Resverlogix Corp. has established a wholly-owned subsidiary called RVX Therapeutics Inc. for business and strategic objectives. Resverlogix Corp. will still hold its primary asset – Nexvas technology for cardiovascular applications. The purpose of RVX Therapeutics is to hold non-core assets (TGFBeta Shield and others) that will develop separately from the Nexvas technology, said a company release.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix’s lead technology program Nexvas applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the “good cholesterol,” to treat cardiovascular diseases.

The Corporation’s second technology program TGF-Beta Shield utilizes an immunomodulating approach to target cancers and fibrotic diseases.